ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

被引：2
|
作者：
Ibrahim, Nuhad
Kim, Sung-Bae
Lin, Nancy
Awada, Ahmad
Gil, Eva Ciruelos
Tonini, Giulia
Vallespir, Bartomeu Piza
Theall, Kathy Puvana
Hamilton, Erika
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, D. A.
    Blakely, L.
    Hemphill, B.
    Joseph, M.
    Liggett, W.
    Daniel, B.
    Castrellon, A.
    Shastry, M.
    Finney, L.
    DeBusk, L.
    Hainsworth, J. D.
    Burris, H. A., III
    CANCER RESEARCH, 2017, 77
  • [22] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)
    Majid, Oneeb
    Xiao, Jianjun Alan
    Sahmoud, Tarek
    Yasuda, Sanae
    Cantagallo, Lisa
    Hamilton, Erika P.
    Pluard, Timothy
    Juric, Dejan
    Gualberto, Antonio
    Husseiin, Ziad
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
    Layman, Rachel M.
    Han, Hyo S.
    Rugo, Hope S.
    Stringer-Reasor, Erica M.
    Specht, Jennifer M.
    Dees, Claire
    Kabos, Peter
    Suzuki, Samuel
    Mutka, Sarah C.
    Sullivan, Brian F.
    Gorbatchevsky, Igor
    Wesolowski, Robert
    LANCET ONCOLOGY, 2024, 25 (04): : 474 - 487
  • [25] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [26] Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
    Juric, Dejan
    Munster, Pamela N.
    Campone, Mario
    Ismail-Khan, Roohi
    Garcia-Estevez, Laura
    Hamilton, Erika Paige
    Becerra, Carlos
    De Boer, Richard H.
    Hui, Rina
    Goncalves, Anthony
    Wang, Yingbo
    Dhuria, Shyeilla V.
    Kalimi, Ghulam H.
    Lorenc, Karen Cristina Rodriguez
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] A phase II open label study of everolimus in combination with antiestrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, Denise A.
    Shastry, Mythili
    DeBusk, Laura M.
    Burris, Howard A., III
    Hainsworth, John D.
    CANCER RESEARCH, 2015, 75
  • [28] Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).
    Moore, Heather M.
    Boni, Valentina
    Bellet, Meritxell
    De Las Heras, Begona Bermejo
    Cortes, Maria Gion
    Oakman, Catherine
    Schmid, Peter
    Trinh, Xuan Bich
    Wheatley, Duncan
    Jhaveri, Komal L.
    Kabos, Peter
    Lim, Elgene
    Velu, Thierry
    Metcalfe, Ciara
    Gates, Mary R.
    Chang, Ching-Wei
    Bond, John
    Goldstein, Leonard D.
    Lauchle, Jennifer O'Hara
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
    Mayer, Erica L.
    Tolaney, Sara M.
    Brufsky, Adam
    Gradishar, William John
    Jhaveri, Komal L.
    Martin, Miguel
    Moscetti, Luca
    Schneeweiss, Andreas
    Vidal, Gregory A.
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC)
    Geyer, Charles
    Bardia, Aditya
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Martin, Miguel
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskiy, Daniil
    Lopez-Valverde, Vanesa
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345